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OBJECTIVES: Hypertension, the leading risk factor for global disease burden, 
affects 20% of Canadians. Approximately 10-15% of hypertensive patients are 
treatment resistant. Controlled clinical trial data demonstrate that catheter-
based renal denervation (RDN) leads to clinically significant blood pressure 
reductions of 32/12 mmHg in treatment resistant patients. The goal of this study 
was to predict the long-term risk reduction and the lifetime cost-effectiveness of 
RDN in a Canadian setting. METHODS: A Markov model with monthly cycles was 
used to estimate: a) ten-year relative risks for clinical endpoints and lifetime 
costs; b) unadjusted and quality-adjusted life expectancy (LYs and QALYs); and c) 
the incremental cost-effectiveness ratio (ICER) of RDN compared to optimal 
pharmacotherapy (OPT) from a Canadian provincial health care system 
perspective. Transition probabilities were based on multivariable risk equations 
(including Framingham) and clinical inputs were based on the Symplicity HTN-2 
trial cohort characteristics. Cost data and utility scores were derived from 
published literature and provincial public databases. The clinical endpoints 
modeled were stroke, myocardial infarction (MI), all coronary artery disease 
(CHD), heart failure (HF), and end-stage renal disease (ESRD). Costs, life 
expectancy, and ICERs were discounted at 3%, and sensitivity and threshold 
analyses were conducted. RESULTS: The 10-year relative risks for RDN versus 
OPT were: stroke 0.70, MI 0.68, all-CHD and HF 0.78, respectively, and ESRD 0.72. 
The lifetime costs of OPT and RDN were $62,076 and $65,471, respectively. RDN 
increased QALYs by 0.60 and LYs by 0.65 compared to OPT. ICERs for RDN were 
$5,648 /QALY and $5,171/LY. Considering willingness-to-pay thresholds of 
$25,000 and $50,000/QALY, RDN was cost-effective down to effect sizes of 18.2 
and 12.2 mmHg systolic blood pressure reductions, respectively. CONCLUSIONS: 
Catheter-based renal denervation, across a wide spectrum of assumptions, is a 
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OBJECTIVES: Ticagrelor showed a significant reduction in major cardiac events 
in patients with acute coronary syndrome (ACS) compared with clopidogrel in 
the Platelet Inhibition and Patient Outcomes (PLATO) trial. Our aim was to assess 
the cost-effectiveness of ticagrelor compared to brand and generic clopidogrel in 
ACS patients from the perspective of the publically funded Canadian health care 
system. METHODS: A two-part model was developed consisting of a one-year 
decision tree and a lifetime Markov model. Within the decision tree, patients 
remained event-free, experienced a non-fatal myocardial infarction (MI), a non-
fatal stroke, or death due to vascular or non-vascular related causes based on 
data from the PLATO trial. The lifetime Markov model followed these patients 
and allowed subsequent MI, stroke and death. Patient level EQ5D (utility) and 
resource use were derived from PLATO. Transition probabilities and Canadian 
unit costs specific were derived from published sources. Univariate and 
probabilistic sensitivity analyses were conducted. RESULTS: In the base case 
analysis, one-year of treatment with ticagrelor post-ACS resulted in a lifetime 
incremental cost-effectiveness ratio (ICER) of $9,745 per quality adjusted life year 
(QALY) gained, assuming the generic cost for clopidogrel. Compared to brand 
clopidogrel, the ICER was $1,523 per QALY gained. A probabilistic sensitivity 
analysis demonstrated a 93% probability of being below $20,000 per QALY gained 
and a 99% probability of being below $30,000 per QALY gained. CONCLUSIONS: 
Ticagrelor is a clinically superior and cost-effective option compared to brand 
and generic clopidogrel for the prevention of major cardiovascular events among 
ACS patients in Canada. These results strongly support the reimbursement of 
ticagrelor for this indication.  
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OBJECTIVES: Severe Aortic stenosis (AS) refers to pathological, clinical and 
pathophysiological changes associated with decreased aortic valve area, as a 
consequence of calcification. Transcatheter Aortic Valve Implantation (TAVI) –is 
targeted at individuals deemed unsuitable candidates for Surgical Aortic Valve 
Replacement (SAVR) as an alternative to Medical Management (MM). Recently 
published studies have demonstrated TAVI to be a good use of health care 
resources in other countries. Our primary objective was to estimate the cost-
effectiveness of TAVI for AS compared with MM in Colombia. METHODS: We 
used an Excel-based probabilistic decision analytic model to evaluate the cost-
effectiveness of TAVI for AS compared to MM. A 3 year update of the landmark 
PARTNER B randomized study was used to inform treatment specific mortality. 
Rates for adverse events and pacemaker use were taken from a large 
multinational registry. Model inputs included costs and resource use for 
inpatient and outpatient treatment in Colombia, and were taken from the 
published literature and local sources. Utilities and quality of life were estimated 
from the PARTNER B study. Additional parameters on local epidemiology were 
obtained from international peer-reviewed literature and private and public 
official databases. Cost-effectiveness was assessed from a third-payer 
perspective and over a 20-year time horizon. RESULTS: Our discounted results 
show that over a patients lifetime, individuals on TAVI obtained 2.55 QALYs and 
those on MM, 0.83 QALYs. The associated lifetime costs for both interventions 
were COP$92 million and COP$8 million for TAVI and MM respectively. The 
incremental cost-effectiveness ratio was therefore $49 million per QALY gained. 
Although TAVI costs were much higher than MM, TAVI improved the probability 
of survival by 12%, resulting in an expected survival gain of 1.25 years. 
CONCLUSIONS: This analysis suggests that TAVI is a cost-effective alternative 
for the treatment of AS in patients unsuitable for SAVR in Colombia.  
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OBJECTIVES: To evaluate the cost-effectiveness of rivaroxaban relative to 
warfarin, for the prevention of stroke in patients with AF. METHODS: A Markov 
model demonstrating the progression of AF patients from healthy state towards 
embolic and bleeding events and to death was adapted to the Turkish setting. 
The cycle length was set as three-months. The analysis was undertaken from a 
payer perspective. Event rates and treatment effects were derived from the 
ROCKET AF clinical trial. Utility values for events were based on international 
literature. Costs of each health state included year 2012 local costs of 
medications, monitoring and events (Mid-2012 USD currency rate was used). 
Incremental cost effectiveness ratios (ICER) per life year (LY) and quality-
adjusted LY (QALY) gained were calculated. One-way sensitivity analyses were 
conducted to test the robustness of the model. The time horizon was life time 
period. Discount rate was set at 3.5% for economic and clinical inputs. 
Willingness-to-pay (WTP) threshold was set as twice the local gross domestic 
product per capita (US$20,888). RESULTS: The total cost of rivaroxaban-treated 
patients was US$1,065 higher compared to warfarin. Additional drug acquisition 
costs (US$3,083) caused by rivaroxaban were mainly offset by reduced 
monitoring (US$1,902) and event costs (US$116). Moreover, rivaroxaban was 
associated with increments of 0.065LYs and 0.055QALY leading to an ICER of 
US$16,362/LY gained and US$19,500/QALY gained. Sensitivity analyses showed 
that the cost-effectiveness results are fairly insensitive to most inputs. The 
changes in the cost of embolic and hemorrhagic events had almost no effect on 
ICER values. The ICER value was sensitive to the cost and frequency of 
monitoring in warfarin patients. CONCLUSIONS: Rivaroxaban, with its cost-
saving effect on monitoring, reducing the frequencies of clinical events, 
improvement in LYs and QALYs, and ICER values below WTP threshold, is 
suggested to be a cost-effective alternative for the prevention of stroke in AF.  
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OBJECTIVES: Rivaroxaban (Xarelto®), an oral direct factor Xa inhibitor, represents 
a new OAC option for stroke prevention in patients with non-valvular atrial 
fibrillation (AF). The objective of this study was to assess the cost effectiveness of 
rivaroxaban in three European countries. METHODS: Markov models for Greece, 
Spain and Slovakia were developed to estimate the cost-effectiveness of 
rivaroxaban and vitamin K antagonist (VKA) treatment from the payer 
perspective of each country. In all three models, baseline event rates (adjusted to 
three month cycles) and relative treatment effects (HRs) were derived from the 
safety on treatment analysis of the ROCKET AF study and available literature. 
Utility values for events used to estimate the quality adjusted life years (QALY) 
were based on literature. Each model used costs and other economic inputs 
specific for that country. One-way and probabilistic sensitivity analyses (PSA) 
were performed. A subpopulation analysis was also conducted for Greece and 
Spain comparing rivaroxaban with VKA in patients with poor INR control 
(patients who spend less than 65% of time in therapeutic range). PSA were also 
performed to assess the robustness of the findings. RESULTS: Base-case analyses 
indicated that rivaroxaban was cost-effective with ICERs of €4,517, €17,432 and 
€11,274 per QALY compared with adjusted-dose warfarin for Greece, Slovakia 
and Spain, respectively. Rivaroxaban was found to be cost-effective in at 
willingness-to-pay thresholds for each country. The analyses conducted for 
patients with poor INR control found that rivaroxaban dominated VKA in this 
patient population in Greece, whereas an ICER of €2144 per QALY compared with 
VKAs were seen in Spain. PSA confirmed the robustness of the results. 
CONCLUSIONS: Rivaroxaban is a cost-effective alternative to VKAs for the 
prevention of stroke in patients with AF, particularly for those patients with poor 
INR control.  
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OBJECTIVES: Warfarin had been the only effective oral anticoagulant (OAC) to 
reduce risk of ischemic stroke in patients with atrial fibrillation (AF) until 
recently new OACs (dabigatran, rivaroxaban and apixaban) became possible 
alternatives for AF patients. Cost-effectiveness of new OACs versus warfarin 
therapy in AF patients was examined. METHODS: A Markov model was designed 
to compare life-long economic and treatment outcomes of apixaban (5mg twice 
daily), dabigatran (150mg twice daily), rivaroxaban (20mg daily), and warfarin 
therapy at anticoagulation care with moderate control on anticoagulation (mean 
time in therapeutic range (TTR) 60.6%) in a hypothetical cohort of AF patients 
aged 65 years old with CHADS2 score 2. Model inputs were derived from 
literature, and outcome measure was incremental cost per quality-adjusted life-
year (QALY) gained (ICER) from the health care provider’s perspective. 
Robustness of model was examined by sensitivity analysis. RESULTS: In the 
base-case scenario, warfarin was the least costly alternative (USD82,768) and it 
gained lowest QALYs (9.571). ICERs of dabigatran and apixaban were USD38,382 
and USD204,787, respectively. Rivaroxaban was more costly and gained less 
QALYs than dabigatran and apixaban. Using USD50,000 as the threshold of 
willingness-to-pay per QALY, dabigatran was the most cost-effective option. The 
most influential factors on the base-case results were the risk of bleeding and 
ischemic stroke of dabigatran comparing to warfarin therapy. In 10,000 Monte 
Carlo simulations, dabigatran was the most likely option to be cost-effective in 
81% of time. CONCLUSIONS: In the present model, the ICER of dabigatran was 
acceptable as the cost-effective alternative when compared to the other new 
OACs and anticoagulation service with moderate anticoagulation control.  
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OBJECTIVES: Estimate the lifetime costs and life-years (LYs) gained associated 
with stroke prevention in patients with nonvalvular atrial fibrillation (NVAF) 
using novel oral anticoagulants (NOACs) apixaban 5 mg, dabigatran 150 mg, and 
rivaroxaban 20 mg relative to warfarin. METHODS: A probabilistic Markov 
decision-analysis model was constructed to evaluate lifetime costs and LYs 
gained for patients receiving NOACs compared to patients receiving adjusted-
dose warfarin. The modeled population was a hypothetical cohort of 70-year old 
patients with NVAF, at an increased risk for stroke (CHADS2≥1), with a renal 
creatinine clearance ≥ 50 mL/min, and no prior contraindications to 
anticoagulation. Rates for clinical events associated with drug efficacy and safety 
were estimated from the RE-LY (dabigatran 150 mg twice daily), ARISTOTLE 
(apixaban 5 mg twice daily), and ROCKET-AF (rivaroxaban 20 mg once daily) 
clinical trials. Medical costs were estimated from a societal perspective and were 
inflated to 2012 US dollars. Sensitivity analyses were conducted to determine 
influential model variables. RESULTS: In the base case, warfarin had the lowest 
cost of $77,843 (standard deviation [SD]: $2,249), followed by rivaroxaban 20 mg 
($78,683±$1,801), dabigatran 150 mg ($82,719±$1,905), and apixaban 5 mg 
($85,350±$1,501). In contrast, warfarin had the highest estimated indirect costs 
($25,485±$58), whereas the estimates were similar for apixaban ($9,499±$6), 
dabigatran ($9,497±$7), and rivaroxaban ($9,514±$6). Apixaban 5 mg yielded the 
highest number of LY’s gained, 13.76 (SD: 0.09), followed by dabigatran 150 mg 
(13.73±0.10), rivaroxaban 20 mg (13.48±0.10), and warfarin (12.98±0.06). The 
model results were dependent upon treatment costs and neurologic events 
associated with rivaroxaban 20 mg. CONCLUSIONS: In patients with NVAF, 
apixaban 5 mg, dabigatran 150 mg, and rivaroxaban 20 mg were more costly 
alternatives to warfarin but appear to result in a higher number of LYs gained.  
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OBJECTIVES: Resistant hypertension is a difficult condition to treat. More than 
5,000 patients with resistant hypertension have undergone surgery catheter 
based renal denervation (RDN) with good results. The primary objective of this 
study was to estimate the cost-effectiveness of catheter based renal denervation 
(RDN) for resistant arterial hypertension compared with standard of care (SC) in 
Colombia. METHODS: Using a previously validated excel-based Markov model, 
we projected the lifetime effect of RDN or standard of care in direct medical costs 
and outcomes. The model considered 6 health states: stroke, myocardial 
infarction, heart failure, end-stage renal disease, angina and death; The relative 
risk associated with RDN compared to SC for stroke (0.77), Myocardial infarction 
(0.74-0.90), Heart Failure (0.73) and end-stage renal disease (0.87) were extracted 
from the literature and converted into transition probabilities. Costs for drugs, 
procedures and other health care resources were obtained from local sources, 
and private and official databases. Life expectancy data was imputed from the 
WHO’s life tables and the utilities for each health state were derived from the 
literature. The analysis was performed using the payer perspective and used an 
annual discount for cost and outcomes of 3%. RESULTS: In our simulation, 
subjects undergoing RDN achieved higher QALY’s (10.27 vs. 9.72) at a higher cost 
during their lifetime (COP$91.406.781 vs. COP$80.799.285). The main drivers for 
these differences were the reduction in complications in the group of subject 
treated with RDN and the costs of treatment. These differences yielded and ICER 
of COP$19.301.843. CONCLUSIONS: Catheter based RDN compared with standard 
care appears to be a favorable strategy for resistant arterial hypertension in 
Colombia, resulting in lower cardiovascular morbidity and mortality and 
decreased renal complications.  
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OBJECTIVES: Atrial Fibrillation (AF) is the most common sustained cardiac 
arrhythmia affecting approximately 40,000 to 80,000 inhabitants in Costa Rica. 
AF increases stroke, thrombo-embolism, deaths, heart failure and 
hospitalizations rates, affecting the quality of life and raising overall costs. 
Literature suggests anticoagulation is the best strategy to prevent strokes and 
reduce death rates in AF. The aim of this study was to assess the cost-
effectiveness (CE) of warfarin against Apixaban, Rivaroxaban, and Dabigatran as 
therapy for AF, from the public health care perspective. METHODS: A simulated 
cohort of patients with AF entered a decision-tree model to compare costs and 
effectiveness of Warfarin (5 mg/day) (comparator), Apixaban (5 mg/12 hours), 
Dabigatran (110 mg/12 hours and 150 mg/12 hours), and Rivaroxaban (20 
mg/day). Effectiveness measures were: stroke, bleeding and myocardial 
infarction (MI) rates and deaths. The model used a lifetime horizon and only 
direct medical costs were considered (inpatient costs, medication expenses, 
adverse events costs, tests). Effectiveness and epidemiologic data were retrieved 
from published literature. Local costs (US$ 2012) were gathered from the Social 
Security of Costa Rica official databases. RESULTS: Apixaban resulted as the less 
expensive option for AF in adult patients and it was the only treatment that 
consistently prevented all three considered diseases: Three MIs, 18 strokes, 54 
bleedings avoided when compared to Warfarin. Mortality rate was found to be 
similar with all strategies implemented. Overall costs were US$43,211,440.23 for 
warfarin, US$38,240,522.33 for Apixaban (lowest), US$38,458,665.03 for 
Dabigatran 110 mg, US$41,055,937.68 for Dabigatran 150 mg, and 
US$42,551,663.86 for Rivaroxaban. In the CE incremental analysis, Apixaban 
appeared as a cost-saving option. Apixaban obtained the highest probability of 
being cost-effective with a 3 GPB per capita in Costa Rica. PSA results support the 
robustness of these findings. CONCLUSIONS: Apixaban resulted as the cost-
saving therapy for AF adult patients in Costa Rica.  
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OBJECTIVES: The aim of the study was to demonstrate the cost effectiveness and 
cost utility of Ivabradine (Procoralan®) in the treatment of patients with Chronic 
Heart Failure (CHF) in Mexico, from the institutional perspective. METHODS: We 
used decision analysis to calculate the cost-effectiveness and cost utility of 2 
competing strategies in the treatment of patients with CHF using the results of 
SHIFT study: 1) Ivabradine plus standard care and 2) standard care. A Markov 
model was developed, the model considers two base case analyses; 29 months 
and extrapolated lifetime. The outcome measure was life years gained (LY) and 
quality adjusted life years (QALY), also incremental cost effectiveness ratio (ICER) 
was performed. Direct health care cost where used and the discount rate was of 
5%. The sensitivity analysis was carrying out in four time horizons: 29 months, 5 
years, 10 years and lifetime. Probabilistic sensitivity analysis was performed. 
RESULTS: Ivabradine plus standard care had more efficacy and less cost in the 
treatment of CHF. The incremental LY and QALY were 0.16 and 0.20, respectively 
on the 29 months analysis and 0.036 and 0.037, respectively for the lifetime 
horizon. The incremental cost using Ivabradine plus standard care was -$37,821 
in the 29 months’ time horizon, while in the lifetime horizon was -$53,710 for 
each LY and QALY. The sensitivity analyses proved that Ivabradine plus 
standard care was cost effective compared to standard care. According to the 
probabilistic sensitivity analyses, the likelihood of Ivabradine plus standard care 
to be cost effective is 100% under the willingness-to-pay threshold in Mexico. 
CONCLUSIONS: evidence from the clinical and the cost effectiveness study prove 
that the use of Ivabradine plus standard care in the treatment of patients with 
CHF is cost effective, and must be considered as first option in the treatment of 
patients with CHF diagnosis.  
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